BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, February 12, 2025
Breaking News: BioWorld by Clarivate releases comprehensive 2024 year in review
See today's BioWorld Science
Home
» Series B financing at Pathios to advance GPR65 inhibitor into clinic for solid cancers
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
Series B financing at Pathios to advance GPR65 inhibitor into clinic for solid cancers
April 19, 2024
No Comments
Pathios Therapeutics Ltd. has raised $25 million in the first close of a series B financing. Proceeds will support continued development of Pathios’ unique approach to cancer immunotherapy focused on GPR65 inhibition.
BioWorld Science
Financings
Cancer
Immuno-oncology
Series B